---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009489"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T19:47:08.954272+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics reports FY 2022 net product sales up 25% to $107.7M; net loss narrows to $182M from $220.7M

## Summary
- Annual net product sales $107.7M (+25% YoY); Q4 net product sales $30.0M (+45% YoY).
- Net loss for FY 2022: $182.0M ($1.67/share) vs $220.7M ($2.24) in 2021; Q4 net loss $19.9M ($0.17).
- ZYNRELEF Q4 net sales $3.9M (+44% QoQ); APONVIE launched March 6, 2023 with CMS pass-through status.
- Oncology care franchise net sales $97.5M in 2022 (+17% YoY); FY 2023 guidance $99M-$103M.
- Cash and investments $84.9M at Dec 31, 2022, down from $157.6M; operating cash used $146.9M in 2022.

## SEC filing metadata
- accession: 0000950170-23-009489
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017023009489/0000950170-23-009489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017023009489/hrtx-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009489
- JSON: https://secwatch.observer/filing/0000950170-23-009489.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009489.txt

## Key facts
- Earnings Releases
  HERON THERAPEUTICS, INC. /DE/ reported the three and twelve months ended December 31, 2022 results: revenue $30.0 million and $107.7 million, net income $19.9 million, or $0.17 per share, and $182.0 million, or $1.67 per share, EPS $0.17 per share and $1.67 per share.
  - Period: the three and twelve months ended December 31, 2022
  - Revenue: $30.0 million and $107.7 million
  - Net income: $19.9 million, or $0.17 per share, and $182.0 million, or $1.67 per share
  - EPS: $0.17 per share and $1.67 per share
  - Result: reported results
  source text: Net product sales for the three and twelve months ended December 31, 2022 were $30.0 million and $107.7 million, respectively, compared to $20.7 million and $86.3 million, respectively, for the same periods in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023009489/0000950170-23-009489-index.htm
- Earnings Releases
  HERON THERAPEUTICS, INC. /DE/ reported full-year 2023 results: revenue $99 million to $103 million. Guidance initiated.
  - Period: full-year 2023
  - Revenue: $99 million to $103 million
  - Guidance: initiated
  - Result: guidance update
  source text: Heron currently expects full-year 2023 net product sales for the oncology care franchise of $99 million to $103 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023009489/0000950170-23-009489-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.